Gynoflor (Estriol, Lactobacillus Acidophilus)

Gynoflor is indicated for several menopause‑related vaginal conditions where estrogen deficiency leads to tissue changes.

• Vulvovaginal atrophy associated with menopause.
• Vaginal dryness that interferes with comfort.
• Dyspareunia (painful intercourse) linked to thinning of the vaginal epithelium.
• Itching or irritation caused by reduced estrogen and altered flora.
• Support of normal vaginal microbiota after antibiotic or hormonal disturbances.
• Adjunct therapy for women using systemic hormone replacement who require localized symptom relief.

The safety profile of Gynoflor reflects the local action of estriol and the probiotic component.

Common

• Mild vaginal irritation or burning at the application site.
• Transient spotting or light bleeding.
• Increased vaginal discharge that is clear or whitish.
• Local itching that resolves with continued use.
• Temporary feeling of warmth in the pelvic area.

Serious

• Allergic reaction such as rash, swelling, or hives.
• Severe vaginal bleeding or ulceration.
• Signs of estrogen‑dependent tumor progression (e.g., abnormal uterine bleeding).
• Persistent pelvic pain or infection.
• Rare thromboembolic events reported with systemic estrogen exposure.
• Unexplained weight gain or fluid retention.

When prescribing Gynoflor, clinicians consider several precautionary factors to ensure safe and appropriate use.

• Not recommended for women with known hypersensitivity to estriol, lactobacilli, or any cream excipients.
• Use with caution in patients with a history of estrogen‑dependent cancers (breast, endometrial, ovarian).
• Avoid in active vaginal infections until they are adequately treated.
• Assess for unexplained vaginal bleeding before initiating therapy.
• Monitor patients with thromboembolic risk or cardiovascular disease.
• Limit duration of use to the shortest period needed for symptom control.

Gynoflor’s local estrogen component can interact with systemic medications that affect hormone pathways or clotting.

Avoid

• Concurrent use of systemic estrogen therapy or high‑dose hormonal contraceptives without medical supervision.
• Antifungal or antibacterial vaginal products that may alter probiotic viability.

Use with caution

• Oral anticoagulants, because estrogen can increase clotting risk.
• Hormone‑sensitive cancer treatments, requiring oncologist oversight.
• Certain selective estrogen receptor modulators (SERMs) that may have opposing effects.
• Systemic corticosteroids, which can affect immune response in the vagina.
• Aromatase inhibitors, as they may reduce overall estrogen levels and affect therapeutic response.